BPC-157 is the most searched peptide on the internet. Your patients are already asking about it. They are finding it on research chemical sites, buying unregulated products, and experimenting without medical supervision. The question for your practice is whether you want to be the physician-supervised option they trust or let them continue buying from sources with no quality controls.
Offering a BPC-157 program is not complicated. It requires a licensed prescriber (which can be provided through a turnkey platform), a relationship with an accredited compounding pharmacy, and a structured program that gives patients access to pharmaceutical-grade product with proper medical oversight.
This guide covers everything you need to know: what BPC-157 is, its current FDA status, how to legally prescribe it, who the right patients are, how to structure a program, and what the economics look like.
What BPC-157 Is and Why Patients Want It
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protein found in human gastric juice. It consists of 15 amino acids and has been studied primarily in animal models for its effects on tissue repair, wound healing, and cytoprotection.
The research base is almost entirely preclinical, but the patient interest is enormous. Patients are drawn to BPC-157 for several reasons:
Musculoskeletal recovery. Studies in animal models show BPC-157 accelerates healing of tendons, ligaments, muscles, and bone. Athletes and active adults with chronic injuries who have not fully responded to standard care represent your largest patient segment.
Gastrointestinal health. BPC-157 has demonstrated gastroprotective effects in animal models, including protection against NSAID-induced gastric damage and benefit in colitis models. Patients with leaky gut, IBD, and chronic GI complaints often seek it out.
Neuroprotection and mood. Animal models suggest BPC-157 may support dopamine system integrity and have anxiolytic effects. Patients dealing with burnout, cognitive fog, or mood issues are an emerging segment.
Post-surgical recovery. Surgeons, orthopedic practices, and surgical recovery centers are increasingly interested in BPC-157 as a recovery support tool following procedures.
The common thread is that these patients are already motivated. They have researched the compound, understand the off-label nature, and are actively seeking a legitimate, physician-supervised source. They are not skeptical buyers; they are searching for a trusted provider.
FDA Regulatory Status in 2026
Understanding the current regulatory landscape is essential before launching a BPC-157 program. The status is evolving.
Current Category II Status
BPC-157 is currently classified by the FDA as a Category II bulk drug substance for purposes of 503A compounding. Category II means the FDA has not yet made a final determination on whether it meets the criteria for compounding (clinical need, safety, effectiveness in the compounded form).
Category II is not an outright ban. Many 503A compounding pharmacies continue to compound BPC-157 for individual patient prescriptions during the review period. However, the regulatory risk is real: the FDA could finalize a determination that restricts compounding of BPC-157, which would affect access.
The July 2026 PCAC Review
The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to review approximately 14 peptides including BPC-157 in July 2026 as part of the broader peptide reclassification process. A favorable review could move BPC-157 to Category 1, which would confirm eligibility for compounding with a valid prescription and remove much of the current regulatory uncertainty.
What This Means for Your Practice
If you launch a BPC-157 program now:
- You can work with 503A pharmacies that currently compound BPC-157
- Your program may need to adjust if the PCAC review results in restrictions
- A favorable July 2026 ruling would strengthen your program’s regulatory footing significantly
- A turnkey platform that actively monitors regulatory changes and maintains pharmacy relationships provides a buffer against disruption
Stay current with FDA guidance through the peptide therapy legal guide and your pharmacy partner’s compliance team.
Who BPC-157 Is Right For
Not every patient is a BPC-157 candidate. Structuring clear intake criteria protects your practice and improves patient outcomes.
Strongest Indications (Highest Patient Satisfaction)
Tendon and ligament injuries. Patients with rotator cuff tendinopathy, patellar tendinitis, Achilles tendinopathy, plantar fasciitis, or lateral epicondylitis who have plateaued with standard physical therapy and conservative care. These patients have clear recovery goals, defined endpoints, and are highly motivated.
Post-surgical recovery. Patients who have undergone orthopedic, spinal, or soft tissue surgery and want to optimize their healing. The window is typically 2 to 6 weeks post-op after surgical wounds have closed.
Chronic musculoskeletal pain. Patients with disc-related back pain, joint degeneration, or chronic muscle strains that have not responded adequately to other interventions.
Gastrointestinal conditions. Patients with a history of NSAID use, IBD, leaky gut, or chronic gastritis who are interested in supportive therapy. Oral formulations are preferred for GI applications.
Athletes and high-performance patients. Active adults who prioritize recovery optimization as part of their training regimen. Often already taking multiple supplements and seeking pharmaceutical-grade options with medical oversight.
Intake Screening
Your intake form should capture:
- Current medications (particularly anticoagulants, which require extra caution with injectables)
- Active cancer diagnosis or history (BPC-157’s angiogenic properties are a theoretical concern)
- Pregnancy or breastfeeding (exclude)
- Current infection at intended injection site (delay)
- Primary goal and target condition
- Previous peptide use (validates interest, captures dosing history)
Patients with active malignancy should generally be excluded given BPC-157’s proangiogenic properties in animal models, even though there is no human data on cancer risk.
How to Structure a BPC-157 Program
A well-structured program creates clear patient expectations, supports consistent dosing, and maximizes retention.
Program Format Options
Injection-only program. The highest-bioavailability option. Suitable for musculoskeletal indications. Patients self-administer subcutaneous injections at home after a brief education session (video or PDF). Most common format.
Oral-only program. Used for gastrointestinal applications. Lower systemic bioavailability but appropriate for GI-targeted effects. Simpler for patients who are averse to injections.
Combination program. Injection plus oral capsule. Covers both systemic and GI applications. Higher price point, typically $299 to $399 per month.
Standard Protocol (Injection)
This is a general framework. Prescribing physicians determine final protocols based on individual patient assessment:
| Parameter | Standard Protocol |
|---|---|
| Dose | 250-500 mcg/day |
| Route | Subcutaneous injection |
| Frequency | Daily or 5x/week |
| Duration | 8-12 week initial course |
| Follow-up | 4-week check-in, 12-week review |
| Maintenance | PRN or ongoing wellness dosing |
Pricing
| Program | Monthly Price | Notes |
|---|---|---|
| BPC-157 Injection | $199-$249 | Standard recovery protocol |
| BPC-157 Oral | $149-$199 | GI-focused, lower dose |
| BPC-157 Combination | $299-$399 | Injection + oral capsule |
| BPC-157 + TB-500 Stack | $349-$449 | Enhanced tissue recovery |
Pricing varies by pharmacy, dose, and market. Most practices price BPC-157 programs in the $200 to $300 range for standard injection protocols.
Compounding Pharmacies for BPC-157
Working with an accredited pharmacy is non-negotiable. BPC-157 quality varies enormously in the unregulated market, and the difference between pharmaceutical-grade product and unverified research chemicals is significant.
Look for:
503A vs 503B status. A 503A compounding pharmacy compounds for individual patients with a valid prescription, which is the standard model for BPC-157. 503B outsourcing facilities produce larger batches and are FDA-registered, but BPC-157 is not on the FDA’s 503B drug shortage list, so it is not typically available from 503B facilities.
PCAB accreditation. The Pharmacy Compounding Accreditation Board (PCAB) accreditation indicates the pharmacy meets rigorous quality standards for equipment, personnel, testing, and processes.
Certificate of Analysis (CoA). Every BPC-157 batch should have a CoA from an independent third-party laboratory confirming purity, potency, and sterility. Request this before working with any pharmacy.
Prescription routing. The best pharmacy partners support electronic prescription routing and direct-to-patient shipping, which is the standard for a telehealth-based program.
A turnkey platform with existing pharmacy relationships removes the need to negotiate individual pharmacy contracts. Relationships with major compounding pharmacies including Empower Pharmacy, Olympia Pharmacy, and Strive Pharmacy are typically included.
The Telehealth Model: Why It Works for BPC-157
BPC-157 prescribing is well-suited for telehealth because:
- Patient evaluation is primarily history-based (intake form + symptom assessment)
- There is no laboratory monitoring required for most protocols
- Medication ships directly to patients
- Follow-up is asynchronous (patient portal messaging)
- Patients are often geographically distributed and prefer remote access
The telehealth prescribing model allows you to serve patients across all 50 states without requiring in-person visits. This is particularly valuable for practitioners who want to offer BPC-157 outside their local market or non-clinical operators who want to launch a national program.
The Economics of a BPC-157 Program
BPC-157 has favorable unit economics compared to most medical programs because pharmacy costs are low relative to subscription pricing.
Unit Economics (Per Patient/Month)
| Revenue | $249/mo (avg) |
|---|---|
| Platform fee (prorated) | -$14 |
| Pharmacy cost per fill | -$40-$60 |
| Provider consultation | -$0-$25 |
| Gross profit per patient | $150-$195/mo |
Gross margin runs 60 to 78 percent depending on your model and pharmacy pricing.
Program Growth Projection
| Month | Active Patients | Monthly Revenue | Monthly Gross Profit |
|---|---|---|---|
| 1 | 10 | $2,490 | $1,500-$1,950 |
| 3 | 25 | $6,225 | $3,750-$4,875 |
| 6 | 50 | $12,450 | $7,500-$9,750 |
| 12 | 100 | $24,900 | $15,000-$19,500 |
Retention is the key variable. BPC-157 patients who achieve initial recovery goals frequently transition to maintenance dosing for general wellness, inflammation management, or ongoing athletic recovery. Average retention of 8 to 10 months is achievable with a structured follow-up protocol.
Adding BPC-157 to an Existing Practice
If you already have patients, BPC-157 is a natural add-on because the conversation is already happening. Patients with chronic injuries, post-surgical recovery needs, or GI complaints will often respond well to the introduction.
A simple script: “Some of my patients with similar injuries have been adding a physician-supervised peptide program to support their recovery alongside their treatment. It is something I can offer if you are interested in learning more.”
Getting Started: The Fastest Path to Launch
Option 1: Through a turnkey platform (1-2 weeks)
A turnkey telehealth platform provides the prescriber network, pharmacy integrations, patient portal, HIPAA infrastructure, and billing in one package. You set up your account, configure your BPC-157 program, add your branding, and begin marketing. The platform handles all clinical and operational back-end.
Setup time: 1 to 2 weeks. No custom development required.
Option 2: Build your own (6-12 months)
Requires EHR selection, pharmacy contract negotiation, prescriber credentialing, HIPAA compliance certification, website and patient portal development, and payment integration. Estimated cost: $55,000 to $125,000.
For most practices and operators, the turnkey path is the clear choice unless you have existing infrastructure that can be adapted.
BPC-157 Is the Entry Point to a Full Peptide Program
Most practices do not stop at one peptide. BPC-157 is often the gateway product because it has the broadest appeal, the clearest use cases, and the most patient demand. Patients who start on BPC-157 for injury recovery often add GHK-Cu for skin quality, TB-500 for broader tissue support, or CJC-1295/Ipamorelin for hormone optimization.
Building a BPC-157 program first gives you the operational infrastructure, patient relationships, and clinical workflows to expand into a full peptide menu without starting from scratch each time.
Explore Karpa Health’s peptide partnership models to find the right fit for your practice.
Have questions about launching a BPC-157 program? Start with our partnership overview or read the complete guide to turnkey peptide telehealth.
Book a call with Karpa Health if you want help structuring the right program.